Novo Nordisk reported results on its next-generation obesity drug in diabetes patients, including data on weight loss that ...

Novo Nordisk shares rose Monday as the company said it would present new data on the ability of semaglutide, the active ...

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...